|Day Low/High||0.36 / 1.14|
|52 Wk Low/High||1.06 / 7.07|
Among other things, the president works to align Democratic senators to support his massive Covid relief bill.
Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.
Here are my takes on stocks in biotech and other companies I own right now.
As long as these charts hold up, I will continue to hold them regardless of what the indices might do.
The fact that the indices are so buoyant on the job news is an illustration of how much skepticism and fear there is.
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
Portola Pharmaceuticals, Flexion Therapeutics and BioDelivery Sciences delivered nice third-quarter numbers.
These names are showing technical characteristics of either bullish or bearish reversal patterns.
We are coming my favorite part of earnings season -- when these small-caps report.
We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.
As always, I am happy to stand in today for Doug Kass here at the Daily Diary. We already are at the midway point of June and coming up on the end of the first half of the year as well. The markets have provided solid returns to this point. although...
Uber's first quarter loss was less than the $991 million loss reported 3 months ago.
These stocks will be great stories in the second half of 2017, and are significantly undervalued.
We answer recent reader questions about three of the biotech stocks we regularly cover.
Not much action in the markets since our last update with the major indices continuing to grind slightly higher as we try to close out a solid first trading week of 2017 on a high note. Think Teva Pharmaceuticals getting oversold today on slightly r...
If you use TVIX and VXX put in an above-market limit order, or if you trade options buy calls on the VIX.
In our last post we discussed large-cap biotech names that have been beaten up in 2016, are cheap and hopefully will see better days in 2017. Here are a few small-cap biotechs I would keep an eye on in 2017. The following is a quick rundown. Aratana...
Which stocks have shown these patterns in the past week.
Thursday felt a lot like capitulation in this space. I was buying.
It appears Twitter will need more than takeover chatter to stay aloft, Oppenheimer analysts say.